title: Potential economic impact of the 21-gene expression assay on the treatment of breast cancer in Brazil.
abstract: OBJECTIVE
  The 21-gene expression assay may support the decision regarding use of chemotherapy in early breast cancer. We sought to investigate the potential impact of incorporating the 21-gene expression assay into private practice in Brazil, from the perspective of third party payers.
  
  
  METHODS
  We conducted a web-based survey with 30 (of a total of approximately 700) Brazilian medical oncologists, who were stratified by State according to the proportion of patients with breast cancer and private health insurance. We evaluated the possible treatment of first choice for patients with lymph-node-negative, estrogen-receptor-positive breast cancer, regardless of menopausal status. Interviewees were not aware of the objective of the study. Responses permitted a quantitative assessment of the care patterns regarding use of different chemotherapy regimens, type of premedication, use of growth factors, and use of intravenous antibiotics for febrile neutropenia. We calculated medication costs using the manufacturer's recommended prices. Other direct medical expenses, indirect medical costs, and non-medical costs were not included.
  
  
  RESULTS
  Considering a hypothetical cohort of 100 patients without access to the 21-gene expression assay, the survey showed that 84 patients would receive chemotherapy. Reclassifying patient eligibility for chemotherapy according to the 21-gene expression assay would lower this number to 49. For a hypothetical cohort of 100 patients with access to the test, US$ 79,361.43 would be saved in main direct medical costs. Such results, however, would greatly vary according to tumor size: the 21-gene expression assay could increase direct medical costs in T1 tumors, and decrease costs in cases with T >2 cm.
  
  
  CONCLUSIONS
  Considering the current price for the 21-gene expression assay in Brazil, our economic analysis suggests that such testing is an overall cost-saving, from the perspective of third party payers. Further, optimal use of resources would entail targeted use of the 21-gene expression assay.
authors.affiliation: Dendrix, Sao Paulo, SP. bacchi@conspat.com.br
authors.forename: Carlos Eduardo
authors.initials: CE
authors.lastname: Bacchi
authors.forename: Flavio
authors.initials: F
authors.lastname: Prisco
authors.forename: Filomena M
authors.initials: FM
authors.lastname: Carvalho
authors.forename: Elida B
authors.initials: EB
authors.lastname: Ojopi
authors.forename: Everardo D
authors.initials: ED
authors.lastname: Saad
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000191:economics*; D003362:Cost-Benefit Analysis; D055088:Early Detection of Cancer; D005260:Female; D020869:Gene Expression Profiling / Q000191:economics* / Q000379:methods; D005820:Genetic Testing / Q000191:economics* / Q000379:methods; D006801:Humans; D009364:Neoplasm Recurrence, Local; D009503:Neutropenia; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity
chemical_list: D000970:Antineoplastic Agents